International Cancer Imaging Society


Our Journal - Cancer Imaging

Our Journal 1
Our Journal 1

 

Cancer Imaging is the official journal of ICIS, an open access, peer-reviewed journal published by BioMed Central. Original articles, as well as reviews and editorials written by international imaging experts with a subspecialty focus on oncology, are published regularly online;  sign up for alerts to keep up-to-date with the latest articles. Cancer Imaging Impact factor for 2016 is 1.470.

The journal encompasses CT, MRI, ultrasound, single photon and positron emission tomography, including multimodality imaging in all kinds of malignant tumours, plus new developments, techniques and innovations.

All articles published in Cancer Imaging are included in PubMed, the most widely used biomedical bibliographic database service, as well as Embase, EmCare, Google Scholar, MEDLINE, Science Citation Index and Scopus. The full text of all research articles is deposited in PubMed Central, the US National Library of Medicine's full-text repository of life science literature.

ICIS Members receive 15% discount on article-processing fees.

Submit your next manuscript to Cancer Imaging and take full advantage of the following:


Members Area


Subscribe to our mailing list

* indicates required
Email Format

Cancer / Oncology News From Medical News Today

New review concludes that evidence for alcohol causing cancer is strong

Published: Fri, 22 Jul 2016 07:00:00 GMT

A new review of epidemiological evidence supports a causal association between alcohol consumption and cancers at seven sites in the body: oropharynx, larynx, oesophagus, liver, colon, rectum and...

Blood disorders cost €23 billion to European economy

Published: Fri, 22 Jul 2016 07:00:00 GMT

Healthcare costs per patient with blood cancers are two times higher than average cancer costs, due to long hospital stays and complex treatment and diagnosis.

Study raises concerns over unnecessary imaging after thyroid cancer

Published: Thu, 21 Jul 2016 12:00:00 GMT

Increased imaging after initial treatment does not necessarily equal better care.

New treatment developed to prevent nausea, vomiting caused by chemo

Published: Thu, 21 Jul 2016 07:00:00 GMT

A drug that blocks neurotransmitters could reduce nausea and vomiting caused by chemotherapy, research co-authored by a Sanford Health physician and published in the New England Journal of Medicine...

Genetic drivers of immune response to cancer discovered through 'big data' analysis

Published: Wed, 20 Jul 2016 12:00:00 GMT

Scientists at the Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified over 100 new genetic regions that affect the immune response to cancer.

Simple measures reduce risk of death in cancer patients in ICU

Published: Wed, 20 Jul 2016 07:00:00 GMT

Daily meetings between physicians, implementation of care protocols and the presence of pharmacists are associated with increase in survival rates.

Some adolescent cancer survivors may require more comprehensive mental health screening

Published: Tue, 19 Jul 2016 12:00:00 GMT

Research from the Childhood Cancer Survivors Study has identified distinct profiles of psychological symptoms in adolescent cancer survivors; a finding that is expected to advance mental health...

Five-year survival data suggest brentuximab vedotin potentially curative in some hodgkin lymphoma patients with limited treatment options

Published: Tue, 19 Jul 2016 12:00:00 GMT

Phase II trial suggests therapy should be standard of care for patients facing relapsed or treatment-resistant Hodgkin lymphoma.

REVLIMID (lenalidomide) approved by the European Commission for the treatment of relapsed/refractory patients with mantle cell lymphoma

Published: Mon, 18 Jul 2016 16:00:00 GMT

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation has announced that the European Commission (EC) has approved REVLIMID® (lenalidomide) for the treatment of adult...

Mayo Clinic scientists develop new combination therapy for advanced cancers

Published: Mon, 18 Jul 2016 11:00:00 GMT

A drug combination designed to enhance the immune system's ability to zero in and attack cancer cells has shown a pronounced therapeutic effect against advanced and metastatic cancers in mice...

Sponsors

Guerbet
Nuada Medical

News

20 June 2016

How I Read Cancer Imaging Studies: The Master Class Series

How I Read Cancer Imaging Studies: The Master Class Series

New articles in our masterclass series:

» Read more » Other news items